Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
2.000
+0.060 (3.09%)
Nov 4, 2024, 4:00 PM EST - Market closed

Immuron Revenue

In the fiscal year ending June 30, 2024, Immuron had annual revenue of 4.90M AUD with 171.67% growth. Immuron had revenue of 2.55M in the half year ending June 30, 2024, with 376.82% growth.

Revenue (ttm)
4.90M AUD
Revenue Growth
+171.67%
P/S Ratio
n/a
Revenue / Employee
700,409 AUD
Employees
7
Market Cap
11.79M USD

Revenue Chart

* This company reports financials in AUD.

History

Fiscal Year End Revenue Change Growth
Jun 30, 20244.90M3.10M171.67%
Jun 30, 20231.80M1.04M135.85%
Jun 30, 2022765.19K619.42K424.91%
Jun 30, 2021145.78K-2.37M-94.21%
Jun 30, 20202.52M131.14K5.49%
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro
Jun 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Cutera 169.19M
Aytu BioPharma 81.00M
Star Equity Holdings 47.15M
STRATA Skin Sciences 32.73M
ImmunoPrecise Antibodies 17.44M
BioRestorative Therapies 174.10K
Revenue Rankings